Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment

Wei Ao, Hong Im Kim, Domenic Tommarello, Kelly A. Conrads, Brian L. Hood, Tracy Litzi, Tamara Abulez, Pang Ning Teng, Clifton L. Dalgard, Xijun Zhang, Matthew D. Wilkerson, Kathleen M. Darcy, Christopher M. Tarney, Neil T. Phippen, Christopher J. Bakkenist, G. Larry Maxwell, Thomas P. Conrads, John I. Risinger, Nicholas W. Bateman*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences